Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenues (Tables)

Revenues (Tables)

6 Months Ended

Jun. 30, 2019

Schedule of revenues disaggregated by category

Revenues disaggregated by category were as follows (in thousands):


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2019		2018		2019		2018
Product sales:
Gross product sales	$	12,481	$	2,287	$	22,397	$	2,287
Discounts and allowances		(2,308)		(500)		(4,170)		(500)
Product sales, net	$	10,173	$	1,787	$	18,227	$	1,787

Revenues from collaborations:
License revenues		—		—		4,499		—
Research and development services		234		—		305		—
Total revenues from collaborations		234		—		4,804		—
Total revenues	$	10,407	$	1,787	$	23,031	$	1,787

Schedule of revenues from product sales disaggregated by customers

The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues (as a percentage of total revenues):


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2019		2018		2019		2018
ASD Healthcare and Oncology Supply		48%		38%		40%		38%
McKesson Specialty Care Distribution Corporation		40%		52%		31%		52%
Cardinal Healthcare		10%		10%		—		10%
Grifols		—		—		20%		—

Schedule of product revenue allowances and discounts

The following table summarizes activity in each of the product revenue allowance and reserve categories for the six months ended June 30, 2019 (in thousands):


	Chargebacks,		Government
	Discounts and		and Other
	Fees		Rebates		Returns		Total
Balance at January 1, 2019	$	622	$	843	$	170	$	1,635
Provision related to current period sales		2,055		1,559		99		3,713
Credit or payments made during the period		(1,682)		(930)		—		(2,612)
Balance at June 30, 2019	$	995	$	1,472	$	269	$	2,736